Show simple item record

dc.contributor.authorGittins, Rosalind
dc.contributor.authorGuirguis, Amira
dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorMaidment, Ian
dc.date.accessioned2018-06-06T17:09:58Z
dc.date.available2018-06-06T17:09:58Z
dc.date.issued2018-03-30
dc.identifier.citationGittins , R , Guirguis , A , Schifano , F & Maidment , I 2018 , ' Exploration of the use of new psychoactive substances by individuals in treatment for substance misuse in the UK. ' , Brain Sciences , vol. 8 , no. 4 , 58 . https://doi.org/10.3390/brainsci8040058
dc.identifier.issn2076-3425
dc.identifier.otherORCID: /0000-0001-8255-0660/work/62748675
dc.identifier.urihttp://hdl.handle.net/2299/20154
dc.descriptionThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
dc.description.abstractSubstance misuse services need to meet the growing demand and needs of individuals using new psychoactive substances (NPS). A review of the literature identified a paucity of research regarding NPS use by these individuals and UK guidelines outline the need for locally tailored strategies. The purpose of this qualitative study was to identify and explore key themes in relation to the use of NPS by individuals receiving community treatment for their substance use. Electronic records identified demographics and semi-structured interviews were undertaken. A thematic analysis of transcripts identified a variety of substance use histories; 50% were prescribed opiate substitutes and 25% used NPS as a primary substance. All were males, age range 26–59 years (SD = 9), who predominantly smoked cannabinoids and snorted/injected stimulant NPS. The type of NPS used was determined by affordability, availability, side-effect profile and desired effects (physical and psychological: 25% reported weight loss as motivation for their use). Poly-pharmacy, supplementation and displacement of other drugs were prevalent. In conclusion, NPS use and associated experiences vary widely among people receiving substance use treatment. Development of effective recovery pathways should be tailored to individuals, and include harm reduction strategies, psychosocial interventions, and effective signposting. Services should be vigilant for NPS use, “on top” use and diversion of prescriptions.en
dc.format.extent20
dc.format.extent691716
dc.language.isoeng
dc.relation.ispartofBrain Sciences
dc.subjectCannabinoids
dc.subjectHarm reduction
dc.subjectNew psychoactive substances
dc.subjectPsychosocial interventions
dc.subjectStimulants
dc.subjectSubstance misuse services
dc.subjectSubstance use
dc.subjectSubstance use treatment
dc.subjectGeneral Neuroscience
dc.titleExploration of the use of new psychoactive substances by individuals in treatment for substance misuse in the UK.en
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85047519172&partnerID=8YFLogxK
rioxxterms.versionofrecord10.3390/brainsci8040058
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record